Galderma Laboratories (Clindagel) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Galderma Laboratories (Clindagel) General Information


The asset is a worldwide rights of clindamycin phosphate gel. The clindamycin phosphate gel comes under the brand name Clindagel® is a prescription topical antibiotic for the treatment of acne. The gel is the only FDA-approved topical formulation of clindamycin phosphate with once daily dose.

Contact Information

Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Onset Dermatologics
Primary Office
  • Avenue Gratta-Paille 2
  • 1018 Lausanne
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Galderma Laboratories (Clindagel) Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Galderma Laboratories (Clindagel)‘s full profile, request access.

Request a free trial